Parkworth Wealth Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Parkworth Wealth Management’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	$255	Buy	+7	New	+$252	﹤0.01%	867

Other funds holding RARE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Parkworth Wealth Management's RARE Position: Q2 2025 in Review

Parkworth Wealth Management opened a new position in Ultragenyx Pharmaceutical (RARE) in Q2 2025: 7 shares worth $255. The stake represents ﹤0.01% of the portfolio and ranks #867 among its holdings.

309 funds tracked by Wall St. Rank hold RARE as of Q2 2025.

Parkworth Wealth Management held 7 shares of Ultragenyx Pharmaceutical worth $255 as of Q2 2025.
Ultragenyx Pharmaceutical was a new Parkworth Wealth Management position in Q2 2025.
Ultragenyx Pharmaceutical made up ﹤0.01% of Parkworth Wealth Management's portfolio in Q2 2025, its #867 holding.
309 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2025.

Based on Parkworth Wealth Management's 13F filing for Q2 2025, filed 13 Aug 2025.